
To investigate the zzso and zzso of zzso human zzso zzso administered by daily subcutaneous injection, in patients with advanced zzso 

Fourteen patients with advanced cancer treated with zzso at escalating dose levels of zzso zzso and zzso zzso on days 1, zzso and zzso The primary zzso of the study were toxicity of zzso and the determination of the zzso of zzso when given by subcutaneous zzso Secondary zzso included effects on blood counts, zzso cell zzso and various zzso zzso 

zzso was well tolerated at all three dose zzso zzso serum levels of zzso were found in patients at the zzso and zzso zzso dose zzso Peak serum zzso levels were achieved about 2 h after injection and zzso was still zzso 8 h after zzso No grade 4 zzso were observed and grade 3 zzso were confined to fever, headache and raised zzso alkaline zzso No consistent zzso or zzso effects were zzso Although therapeutic efficacy was not an zzso one complete response zzso disease) was zzso One patient with chronic zzso leukemia progressed on zzso 

zzso up to zzso zzso is well tolerated when given by subcutaneous zzso zzso relevant serum zzso levels can be achieved and sustained for at least 8 h after a single zzso 

